These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36882249)

  • 1. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink.
    Cook S; Schmedt N; Broughton J; Kalra PA; Tomlinson LA; Quint JK
    BMJ Open; 2023 Mar; 13(3):e065927. PubMed ID: 36882249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care.
    Metsärinne K; Bröijersen A; Kantola I; Niskanen L; Rissanen A; Appelroth T; Pöntynen N; Poussa T; Koivisto V; Virkamäki A;
    Prim Care Diabetes; 2015 Feb; 9(1):31-8. PubMed ID: 25066820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
    Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
    Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
    Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A
    BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
    Shubrook JH; Neumiller JJ; Wright E
    Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
    Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
    Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study.
    Folkerts K; Kelly AMB; Petruski-Ivleva N; Fried L; Blankenburg M; Gay A; Velentgas P; Kovesdy CP
    Nephron; 2021; 145(4):342-352. PubMed ID: 33789294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years.
    Lawson CA; Seidu S; Zaccardi F; McCann G; Kadam UT; Davies MJ; Lam CS; Heerspink HL; Khunti K
    EClinicalMedicine; 2021 Feb; 32():100739. PubMed ID: 33688855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.
    Forbes AK; Hinton W; Feher MD; Elson W; Joy M; Ordóñez-Mena JM; Fan X; Cole NI; Banerjee D; Suckling RJ; de Lusignan S; Swift PA
    EClinicalMedicine; 2024 Feb; 68():102426. PubMed ID: 38304744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study.
    Mata-Cases M; Franch-Nadal J; Real J; Cedenilla M; Mauricio D
    BMJ Open; 2019 Oct; 9(10):e031281. PubMed ID: 31662386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
    Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
    Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of chronic kidney disease in the Netherlands and its cardiovascular and renal complications.
    Vervloet MG; de Jong HJ; Pander J; Overbeek JA
    BMC Nephrol; 2023 Nov; 24(1):337. PubMed ID: 37957561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between practice coding of chronic kidney disease (CKD) in primary care and subsequent hospitalisations and death: a cohort analysis using national audit data.
    Cleary F; Kim L; Prieto-Merino D; Wheeler D; Steenkamp R; Fluck R; Adlam D; Denaxas S; Griffith K; Loud F; Hull S; Caplin B; Nitsch D
    BMJ Open; 2022 Oct; 12(10):e064513. PubMed ID: 36220323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants and burden of chronic kidney disease in the population-based CoLaus study: a cross-sectional analysis.
    Ponte B; Pruijm M; Marques-Vidal P; Martin PY; Burnier M; Paccaud F; Waeber G; Vollenweider P; Bochud M
    Nephrol Dial Transplant; 2013 Sep; 28(9):2329-39. PubMed ID: 23825103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.